サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1519701

ナルコレプシー治療薬市場レポート：タイプ別、疾患タイプ別、治療タイプ別、地域別、2024年～2032年

Narcolepsy Drugs Market Report by Type, Disease Type, Therapeutic Type, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 147 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ナルコレプシー治療薬市場レポート：タイプ別、疾患タイプ別、治療タイプ別、地域別、2024年～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のナルコレプシー治療薬の市場規模は2023年に33億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに62億米ドルに達し、2024年から2032年の間に6.99%の成長率（CAGR）を示すと予測しています。

ナルコレプシー治療薬とは、慢性睡眠障害の治療に用いられる医薬品を指します。この疾患は、日中の過度の眠気（EDS）、カタプレキシーまたは突然の筋力低下、睡眠麻痺、幻覚、断片的な睡眠、不眠を特徴とします。その他の症状として、意識によらない自動行動、目のかすみ、複視、眼瞼下垂、精神機能の障害などがあります。ナルコレプシーに罹患している患者は、1日の睡眠時間は健常者と同じであるが、睡眠の質は低下する傾向があります。一般的に使用されるナルコレプシー治療薬には、中枢神経刺激薬、オキシベートナトリウム、選択的セロトニン再取り込み阻害薬、三環系抗うつ薬などがあります。これらの薬剤は成人患者の覚醒を改善し、幻覚、眠気、カタプレキシーを最小限に抑えるのに役立ちます。

ナルコレプシー治療薬の市場動向：

世界中でナルコレプシーの有病率が増加していることが、市場の成長を促す主な要因の1つです。これは、労働人口の座りがちなライフスタイルと多忙なスケジュールが、睡眠関連障害の発生を著しく増加させていることに起因しています。さらに、大衆の健康意識の高まりと、利用可能な治療法に関する意識の高まりが、市場の成長を後押ししています。これに伴い、小児のナルコレプシー治療にオキシベートナトリウムが広く採用されていることも、市場の成長に寄与しています。さらに、ナルコレプシーの診断技術の大幅な向上も成長を促す要因となっています。製薬メーカーも、長期的な効果と副作用の軽減を実現した変種を開発しています。このような病気にかかりやすい老年人口が増加していることや、神経学分野における広範な研究開発（R&D）活動など、その他の要因も市場の成長を後押しすると予想されます。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のナルコレプシー治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • ナルコレプシーと脱力発作
    • 市場動向
    • 市場予測
  • 脱力発作を伴わないナルコレプシー
    • 市場動向
    • 市場予測
  • 二次性ナルコレプシー
    • 市場動向
    • 市場予測

第7章 市場内訳：疾患別

  • 日中の極度の眠気
    • 市場動向
    • 市場予測
  • 脱力発作
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：治療タイプ別

  • オキシベートナトリウム
    • 市場動向
    • 市場予測
  • 中枢神経刺激薬
    • 市場動向
    • 市場予測
  • 三環系抗うつ薬
    • 市場動向
    • 市場予測
  • 選択的セロトニン再取り込み阻害剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Avadel Pharmaceuticals plc
    • Axsome Therapeutics Inc.
    • Bioprojet Pharma
    • Graymark Healthcare Inc.
    • Jazz Pharmaceuticals plc
    • Ligand Pharmaceuticals Incorporated
    • Novartis AG
    • SHIONOGI & Co. Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Narcolepsy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Narcolepsy Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Narcolepsy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Narcolepsy Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Narcolepsy Drugs Market: Breakup by Disease Type (in %), 2023
  • Figure 6: Global: Narcolepsy Drugs Market: Breakup by Therapeutic Type (in %), 2023
  • Figure 7: Global: Narcolepsy Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Narcolepsy Drugs (Narcolepsy with Cataplexy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Narcolepsy Drugs (Narcolepsy with Cataplexy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Narcolepsy Drugs (Narcolepsy without Cataplexy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Narcolepsy Drugs (Narcolepsy without Cataplexy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Narcolepsy Drugs (Secondary Narcolepsy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Narcolepsy Drugs (Secondary Narcolepsy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Narcolepsy Drugs (Daytime Extreme Sleepiness) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Narcolepsy Drugs (Daytime Extreme Sleepiness) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Narcolepsy Drugs (Cataplexia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Narcolepsy Drugs (Cataplexia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Narcolepsy Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Narcolepsy Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Narcolepsy Drugs (Sodium Oxybate) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Narcolepsy Drugs (Sodium Oxybate) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Narcolepsy Drugs (Central Nervous System Stimulants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Narcolepsy Drugs (Central Nervous System Stimulants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Narcolepsy Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Narcolepsy Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Narcolepsy Drugs (Selective Serotonin Reuptake Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Narcolepsy Drugs (Selective Serotonin Reuptake Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Narcolepsy Drugs (Other Therapeutic Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Narcolepsy Drugs (Other Therapeutic Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Narcolepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Narcolepsy Drugs Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Narcolepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Narcolepsy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Narcolepsy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Narcolepsy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Narcolepsy Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Narcolepsy Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Narcolepsy Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Narcolepsy Drugs Market Forecast: Breakup by Therapeutic Type (in Million US$), 2024-2032
  • Table 5: Global: Narcolepsy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Narcolepsy Drugs Market: Competitive Structure
  • Table 7: Global: Narcolepsy Drugs Market: Key Players
目次
Product Code: SR112024A5685

The global narcolepsy drugs market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.99% during 2024-2032.

Narcolepsy drugs refer to pharmaceutical medicines used for the treatment of chronic sleep disorders. The disorder is characterized by excessive daytime sleepiness (EDS), cataplexy or sudden loss of muscle strength, sleep paralysis, hallucinations, fragmented sleep and insomnia. Additional symptoms may include automatic behaviors without conscious awareness, blurred vision, double vision or droopy eyelids and disturbed mental functioning. Patients suffering from narcolepsy tend to sleep the same number of hours per day as normal individuals; however, sleep quality tends to be poorer. Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants. These drugs aid in improving wakefulness in adult patients and minimizing hallucinations, sleepiness and cataplexy.

Narcolepsy Drugs Market Trends:

The increasing prevalence of narcolepsy across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the working population, which, in turn, is significantly increasing the incidences of sleep-related disorders. Moreover, rising health consciousness among the masses and the increasing awareness regarding the available treatment alternatives are providing a thrust to the market growth. In line with this, the widespread adoption of sodium oxybate for the treatment of narcolepsy in children is also contributing to the growth of the market. Additionally, significant improvements in the diagnostic technologies for narcolepsy are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing variants with long-term benefits and reduced side effects. Other factors, including the rising geriatric population, which is more susceptible to such ailments, along with extensive research and development (R&D) activities in the field of neurology, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global narcolepsy drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, disease type and therapeutic type.

Breakup by Type:

Narcolepsy with Cataplexy

Narcolepsy without Cataplexy

Secondary Narcolepsy

Breakup by Disease Type:

Daytime Extreme Sleepiness

Cataplexia

Others

Breakup by Therapeutic Type:

Sodium Oxybate

Central Nervous System Stimulants

Tricyclic Antidepressants

Selective Serotonin Reuptake Inhibitor

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Bioprojet Pharma, Graymark Healthcare Inc., Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis AG, SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global narcolepsy drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global narcolepsy drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the disease type?
  • What is the breakup of the market based on the therapeutic type?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global narcolepsy drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Narcolepsy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Narcolepsy with Cataplexy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Narcolepsy without Cataplexy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Secondary Narcolepsy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Daytime Extreme Sleepiness
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cataplexia
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Therapeutic Type

  • 8.1 Sodium Oxybate
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Central Nervous System Stimulants
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Tricyclic Antidepressants
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Selective Serotonin Reuptake Inhibitor
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Avadel Pharmaceuticals plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Axsome Therapeutics Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Bioprojet Pharma
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Graymark Healthcare Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Jazz Pharmaceuticals plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Ligand Pharmaceuticals Incorporated
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 SHIONOGI & Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis